Deal snapshot: Roche’s third partnership around small molecule, RNA-targeted therapies taps Ribometrix’s three-dimensional structural analysis of RNA to find pockets amenable to small molecule drugs.

In addition to its near-monopoly in cystic fibrosis, the US biotech behemoth is continuing its deal-making in other areas and has become the latest company to link up with Skyhawk.

China was a focus of discussions at the 2020 J.P. Morgan Healthcare Conference, as a Phase One trade agreement was signed to end a 17-month dispute with the US. Patent linkage and IP protection enforcement are also being closely watched, while Chinese firms including BeiGene continue to make strides in oncology deal-making.

BeiGene’s license agreement with Leap Therapeutics covers Asia, except for Japan, along with Australia and New Zealand. Apollomics obtains rights in China and beyond to GlycoMimetics’ e-selectin antagonists.